Loading...
Loading...
Rodman & Renshaw terminated its coverage of Biostar Pharmaceuticals
BSPM. The rating agency's last rating on the company's stock was Market Outperform with a price target of 7. On Friday, BSPM added 5.22% to its value to finish the week at $1.41.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst RatingsRodman and Renshaw
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in